Amarantus Bioscience - AMBS.
Company's patented MANF technology will benefit.
Potential takeover target. Amgen is a potential suitor.
It's currently trading under a dime.
Best opportunity in the market for substantial profits both short and long term.
AMBS is substantially undervalued. Currently trading below a dime.
One of Amgen's co-founders, Dr. Joseph Rubinfeld, is on the company's scientific advisory board.